Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein
Journal of Medicinal Chemistry · 09.01.2025 · 68 (1) · 81-94
DOI: 10.1021/acs.jmedchem.4c01424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.12.2024. Verfasst von Yafeng Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Protein Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The rearranged-during-transfection (RET) kinase is a validated target for the treatment of RET-altered cancers. Currently approved RET-selective kinase inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), increase the oncogenic RET protein level upon treatment, which may affect their efficacy. We seek to reduce the oncogenic RET protein level and RET kinase activity simultaneously. Here, we report the development of proteolysis targeting chimera (PROTAC) degraders of oncogenic RET protein. Compound YW-N-7 exhibited dual action of selectively inhibiting and depleting RET protein both in vitro and in vivo. Proteomic analysis indicated that YW-N-7 is highly specific to RET. In cell cultures, reducing RET fusion protein potentiated the activity of LOXO-292. Furthermore, YW-N-7 showed significant activity in inhibiting KIF5B-RET-driven xenograft tumors in animals. This study exemplifies the feasibility of simultaneously inhibiting and degrading oncogenic RET kinase for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States.
- Peggy and Charles Stephenson Cancer Center and Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
- Early-Phase Drug Development, Sarah Cannon Research Institute, Nashville, Tennessee 37203, United States.
- Department of Biochemistry and Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States.
ORCID-Profile: Blaine H M Mooers, Jianfeng Cai
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Wang, Y., Hu, X., Pandey, S., Khatri, U., Shen, T., Subbiah, V., Mooers, B. H. M., Chao, T., Wang, S., Yu, H., Sun, X., Wu, J., & Cai, J. (2025). Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. Journal of Medicinal Chemistry, 68(1), 81-94. https://doi.org/10.1021/acs.jmedchem.4c01424
Vancouver
Wang Y, Hu X, Pandey S, Khatri U, Shen T, Subbiah V, et al. Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. Journal of Medicinal Chemistry. 2025;68(1):81-94. doi:10.1021/acs.jmedchem.4c01424
BibTeX
@article{Wang2025,
author = {Wang, Yafeng and Hu, Xueqing and Pandey, Shriya and Khatri, Ujjwol and Shen, Tao and Subbiah, Vivek and Mooers, Blaine H M and Chao, Ting and Wang, Shaohui and Yu, Huaxuan and Sun, Xingmin and Wu, Jie and Cai, Jianfeng},
title = {Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {1},
pages = {81--94},
doi = {10.1021/acs.jmedchem.4c01424}
}
EUVIMED